Gastroenteropancreatic Neuroendocrine Tumor
📧 Sign up to get email alerts when something new happens for Gastroenteropancreatic Neuroendocrine Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-09-03Clinical Trial Update: Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer [Phase 2]
Phase 2 study assessing bevacizumab in combination with FOLFIRI as second-line therapy for advanced, inoperable poorly differentiated neuroe…
-
CLINICAL_TRIALS research · 2025-08-15Clinical Trial Update: Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET [Phase 1, Phase 2]
Clinical trial update describing a Phase 1/2 study of nanoliposomal irinotecan (nal-IRI, Onivyde) in combination with carboplatin for advanc…
-
CLINICAL_TRIALS research · 2025-08-07Clinical Trial Update: NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas [Phase 1]
Phase 1 clinical trial update for NP-101 (TQ Formula) in combination with nivolumab and ipilimumab for advanced or metastatic extra-pulmonar…
-
CLINICAL_TRIALS research · 2025-07-23Clinical Trial Update: Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases [Phase 2]
Phase 2 trial evaluating intra-arterial hepatic infusion of radiolabeled somatostatin analogs in patients with gastroenteropancreatic neuroe…
-
CLINICAL_TRIALS trial_result · 2025-07-09Clinical Trial Update: Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors [Phase 1, Phase 2]
A pharmacokinetic study evaluating the combination of lurbinectedin and irinotecan in selected solid tumors has completed (Phase 1/Phase 2).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-06-03Clinical Trial Update: Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors [Phase 3]
A Phase 3 clinical trial is evaluating Gallium-68 Edotreotide PET/CT imaging for patients with advanced gastroenteropancreatic neuroendocrin…
-
CLINICAL_TRIALS research · 2025-05-02Clinical Trial Update: Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver [EARLY_Phase 1]
This clinical trial update describes an early-phase study of Lutathera in people with gastroenteropancreatic, bronchial, or unknown primary …
-
CLINICAL_TRIALS trial_result · 2025-03-28Clinical Trial Update: Nutrition in Gastroenteropancreatic Neuroendocrine Tumor
This clinical trial update reports results from a nutrition-focused study in patients with gastroenteropancreatic neuroendocrine tumors.
-
CLINICAL_TRIALS trial_result · 2025-03-03Clinical Trial Update: A Transfer Learning Radiomics Model for Predicting Response to Initial Transarterial Embolization in Patients with Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases
Clinical trial update indicating the study completed on using a transfer learning radiomics model to predict response to initial transarteri…
-
CLINICAL_TRIALS trial_result · 2025-02-24Clinical Trial Update: 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer. [Phase 1]
Phase 1 clinical trial evaluating the radiopharmaceutical 177Lu-PP-F11N for receptor-targeted therapy and imaging in metastatic medullary th…
-
CLINICAL_TRIALS trial_result · 2025-01-13Clinical Trial Update: Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. [Phase 2]
This is a phase 2 trial evaluating the combination of platinum-doublet chemotherapy with nivolumab for gastroenteropancreatic neuroendocrine…
-
CLINICAL_TRIALS trial_result · 2025-01-13Clinical Trial Update: Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors [Phase 1, Phase 2]
The document reports a completed Phase 1/Phase 2 trial evaluating Lutetium-177 dotatate in combination with metronomic capecitabine for aggr…
-
CLINICAL_TRIALS trial_result · 2025-01-13Clinical Trial Update: Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors [Phase 2]
Phase 2 trial of 177Lu-DOTATATE for advanced gastroenteropancreatic neuroendocrine tumors was terminated.
-
CLINICAL_TRIALS trial_result · 2025-01-09Clinical Trial Update: Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin [Phase 2]
A phase 2 trial evaluating the combination of durvalumab and tremelimumab in advanced gastroenteropancreatic and lung-origin neuroendocrine …
-
CLINICAL_TRIALS trial_result · 2025-01-06Clinical Trial Update: A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment [NA]
A completed study evaluating whether circulating tumor DNA can be used in follow-up of patients with advanced gastroenteropancreatic or lung…
-
CLINICAL_TRIALS trial_result · 2024-12-24Clinical Trial Update: A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly
A completed clinical trial update from Ipsen studying participants’ experiences with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)…
-
CLINICAL_TRIALS trial_result · 2024-11-27Clinical Trial Update: Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs [Phase 2]
Phase 2 study evaluating safety and dosimetry of Lutathera (lutetium-177 DOTATATE) in adolescent patients with gastroenteropancreatic neuroe…
-
FDA approval · 2024-10-25FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Gland Pharma Limited)
FDA approved a supplemental application for Octreotide acetate submitted by Gland Pharma Limited.
-
CLINICAL_TRIALS trial_result · 2024-10-10Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET [Phase 3]
Phase 3 study to evaluate Lutathera (lutetium Lu-177 dotatate) in patients with grade 2/3 advanced gastroenteropancreatic neuroendocrine tum…
-
CLINICAL_TRIALS trial_result · 2024-10-01Clinical Trial Update: Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs [Phase 3]
Phase 3 study in Chinese participants with gastroenteropancreatic neuroendocrine tumors has completed, with results posted.
-
FDA approval · 2024-09-27FDA Approved: BYNFEZIA PEN — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved BYNFEZIA PEN (octreotide acetate) under an original NDA from Sun Pharmaceutical Industries. The product is an autoinjector pen …
-
CLINICAL_TRIALS trial_result · 2024-09-25Clinical Trial Update: Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors [Phase 2]
Phase 2 trial evaluating everolimus after chemoembolization for liver metastases from digestive gastroenteropancreatic neuroendocrine tumors…
-
CLINICAL_TRIALS research · 2024-08-26Clinical Trial Update: A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET) [Phase 2]
Phase 2 clinical trial evaluating the efficacy, safety, and pharmacokinetics of subcutaneous octreotide in patients with gastroenteropancrea…
-
CLINICAL_TRIALS trial_result · 2024-08-09Clinical Trial Update: A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea
This document reports the completion of a post-marketing surveillance study of Lutathera (lutetium Lu-177 dotatate) in Korean patients with …
-
FDA approval · 2024-07-09FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
The FDA approved a supplemental application for octreotide acetate (ANDA 203765) submitted by Heritage Pharmaceuticals d/b/a Avet Pharmaceut…